한빛사논문
- 조회351
전북대학교, St George’s University of London
Mi-Young Kim 1,2, Emil Vergara 2, Andy Tran 2, Matthew John Paul 2, Tae-Ho Kwon 3, Julian K.C. Ma 2, Yong-Suk Jang 1,* and Rajko Reljic 2,*
1Department of Molecular Biology, Jeonbuk National University, Jeonju, Republic of Korea
2Institute for Infection and Immunity, St George’s University of London, London, UK
3Gencellbiotech Inc., Wanju, Republic of Korea
*Corresponding authors: correspondence to Yong-Suk Jang or Rajko Reljic
Abstract
Immunoglobulin G (IgG)-based fusion proteins have been widely exploited as a potential vaccine delivery platform but in the absence of exogenous adjuvants, the lack of robust immunity remains an obstacle. Here, we report on a key modification that overcomes that obstacle. Thus, we constructed an IgG-Fc vaccine platform for dengue, termed D-PCF, which in addition to a dengue antigen incorporates the cholera toxin non-toxic B subunit (CTB) as a molecular adjuvant, with all three proteins expressed as a single polypeptide. Following expression in Nicotiana benthamiana plants, the D-PCF assembled as polymeric structures of similar size to human IgM, a process driven by the pentamerization of CTB. A marked improvement of functional properties in vitro and immunogenicity in vivo over a previous iteration of the Fc-fusion protein without CTB [1] was demonstrated. These include enhanced antigen presenting cell binding, internalization and activation, complement activation, epithelial cell interactions and ganglioside binding, as well as more efficient polymerization within the expression host. Following immunization of mice with D-PCF by a combination of systemic and mucosal (intranasal) routes, we observed robust systemic and mucosal immune responses, as well as systemic T cell responses, significantly higher than those induced by a related Fc-fusion protein but without CTB. The induced antibodies could bind to the domain III of the dengue virus envelope protein from all four dengue serotypes. Finally, we also demonstrated feasibility of aerosolization of D-PCF as a prerequisite for vaccine delivery by the respiratory route.
논문정보
- Research article
- 2024년 01월 (BRIC 등록일 2024-01-03)
- 국내(교신)+국외 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
